Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 26,636 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Postpartum Complication, Posttraumatic Stress Symptoms
Interventions: Prenatal Education on Childbirth; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma
Interventions: Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, Placebo eye drops; Drug · Procedure · Other
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Grand Junction, Colorado • Oklahoma City, Oklahoma • El Paso, Texas

Conditions: Healthy Participants
Interventions: BMS-986465, Placebo, Pegasys, Famotidine; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Anaheim, California • Austin, Texas

Conditions: Atrial Fibrillation
Interventions: HBI-3000, Placebo; Drug
Lead sponsor: HUYABIO International, LLC.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Naples, Florida • Springfield, Illinois • Tupelo, Mississippi + 1 more

Conditions: Cancer
Interventions: Oral lapatinib tablets or placebo tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 20
States / cities: Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more

Conditions: Autism Spectrum Disorders
Interventions: Intranasal Oxytocin (Trade name: Syntocinon); Drug
Lead sponsor: Robert Schultz; Other
Eligibility: 12 Years to 17 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Celiac Disease
Interventions: Latiglutenase, Placebo; Drug · Other
Lead sponsor: Immunogenics, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: 50 mg Usnoflast, 75 mg Usnoflast, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: La Jolla, California • Orange, California • San Francisco, California + 12 more

Conditions: Inflammation, Inflammatory Response
Interventions: Marine Lipid Oil Concentrate, Dietary Supplement, Placebo; Dietary Supplement
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: HIV, Therapeutic Vaccine
Interventions: rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: MGD-Meibomian Gland Dysfunction
Interventions: Thermal Vectored Pulsation; Device
Lead sponsor: Dunes Eye Consultants; Other
Eligibility: 25 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dakota Dunes, South Dakota

Conditions: Systemic Lupus Erythematosus, Healthy
Interventions: JNJ-55920839, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, Minnesota • Durham, North Carolina

Conditions: Open-Angle Glaucoma
Interventions: VISCO360 ab interno canaloplasty surgery, Selective Laser Trabeculoplasty (SLT); Device
Lead sponsor: Sight Sciences, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Orange, California • Oklahoma City, Oklahoma + 3 more

Conditions: Osteoarthritis, Knee
Interventions: GID SVF-2 Device System; Device
Lead sponsor: GID BIO, Inc.; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 9
States / cities: Sacramento, California • Coral Springs, Florida • New Orleans, Louisiana + 6 more

Conditions: Autoimmune Diseases, Mental Disorders Diagnosed in Childhood, Schizophrenia
Interventions: Intravenous immunoglobulin; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypereosinophilic Syndrome
Interventions: Depemokimab, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: San Diego, California • Atlanta, Georgia • Manhasset, New York + 2 more

Conditions: Anemia
Interventions: Ferric Carboxymaltose, Standard Medical Care (SMC); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Prostate Cancer
Interventions: Trimethoprim Tablets; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Migraine
Interventions: Metformin, Matching Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: dronedarone (SR33589), placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 70 Years and older
Enrollment: 4,628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Chronic Kidney Disease, Proteinuria
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more

Conditions: Allergic Rhinitis Due to Grass Pollens
Interventions: 300 IR, Placebo; Drug
Lead sponsor: Stallergenes Greer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 19
States / cities: Normal, Illinois • Lexington, Kentucky • Owensboro, Kentucky + 16 more

Conditions: Rheumatoid Arthritis
Interventions: Canakinumab (investigational), Placebo, Methotrexate (MTX); Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Paradise Valley, Arizona + 14 more

Conditions: Lupus Nephritis
Interventions: BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 26
States / cities: Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more

Search by objective public record fields.

Labor Education to Reduce Postpartum Traumatic Stress

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Intranasal Oxytocin and Learning in Autism

Latiglutenase as a Treatment for Celiac Disease

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

A Study to Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation

Therapeutic Vaccine for HIV

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma

Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis

Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

Folate Study in Men With Advanced Prostate Cancer

Metformin for the Prevention of Episodic Migraine (MPEM)

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis